FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$2.5B
This Quarter Return
-3.63%
1 Year Return
+52.94%
3 Year Return
+530.54%
5 Year Return
–
10 Year Return
–
AUM
$2.14B
AUM Growth
+$2.14B
(-9.8%)
Cap. Flow
-$56.2M
Cap. Flow
% of AUM
-2.63%
Top 10 Holdings %
Top 10 Hldgs %
61.97%
Holding
57
New
7
Increased
13
Reduced
4
Closed
8
Top Buys
| 1 |
Disc Medicine
IRON
|
$43.7M |
| 2 |
Erasca
ERAS
|
$38.3M |
| 3 |
AnaptysBio
ANAB
|
$31.7M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
$17.5M |
| 5 |
Savara
SVRA
|
$16.8M |
Top Sells
Sector Composition
| 1 | Healthcare | 99.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
NewAmsterdam Pharma
NAMS
$2.71B
| $235M | 10.99% | 12,226,943 | – | – |
|
2
Mirum Pharmaceuticals
MIRM
$3.71B
| $222M | 10.39% | 6,495,392 | – | – |
|
3
Krystal Biotech
KRYS
$4.27B
| $182M | 8.49% | 988,460 | – | – |
|
4
HilleVax
HLVX
$105M
| $154M | 7.18% | 10,617,062 +835,590 | +9% | +$12.1M |
|
5
Phathom Pharmaceuticals
PHAT
$864M
| $104M | 4.87% | 10,109,279 | – | – |
|
6
Rhythm Pharmaceuticals
RYTM
$6.85B
| $97.4M | 4.55% | 2,371,304 +181,125 | +8% | +$7.44M |
|
7
BridgeBio Pharma
BBIO
$9.89B
| $92M | 4.3% | 3,632,604 +217,000 | +6% | +$5.5M |
|
8
Arcutis Biotherapeutics
ARQT
$1.86B
| $81.7M | 3.82% | 8,785,284 | – | – |
|
|
9
Disc Medicine
IRON
$2.07B
| $79.1M | 3.7% | 1,754,834 +969,834 | +124% | +$43.7M |
|
10
Vaxcyte
PCVX
$4B
| $78.5M | 3.67% | 1,039,405 -100,000 | -9% | -$7.55M |
|
11
Edgewise Therapeutics
EWTX
$1.51B
| $67.2M | 3.14% | 3,731,067 +427,500 | +13% | +$7.7M |
|
|
12
AnaptysBio
ANAB
$569M
| $54.3M | 2.54% | 2,165,591 +1,265,891 | +141% | +$31.7M |
|
|
VRNA
13
Verona Pharma
VRNA
$9.16B
| $47.9M | 2.24% | 3,314,349 +300,000 | +10% | +$4.34M |
|
14
KalVista Pharmaceuticals
KALV
$678M
| $43.4M | 2.03% | 3,687,867 | – | – |
|
15
Tarsus Pharmaceuticals
TARS
$2.47B
| $43.1M | 2.02% | 1,587,527 -200,000 | -11% | -$5.44M |
|
16
Revolution Medicines
RVMD
$7.1B
| $38.7M | 1.81% | 997,455 | – | – |
|
|
17
Erasca
ERAS
$445M
| $38.3M | 1.79% | +16,216,216 | New | +$38.3M |
|
18
Agios Pharmaceuticals
AGIO
$2.19B
| $37.6M | 1.76% | 871,974 +348,808 | +67% | +$15M |
|
19
Soleno Therapeutics
SLNO
$3.6B
| $35.7M | 1.67% | 875,667 | – | – |
|
20
Rocket Pharmaceuticals
RCKT
$354M
| $33.6M | 1.57% | 1,561,230 | – | – |
|
|
21
Savara
SVRA
$567M
| $32.9M | 1.54% | 8,157,385 +4,157,385 | +104% | +$16.8M |
|
22
Oric Pharmaceuticals
ORIC
$994M
| $29.3M | 1.37% | 4,142,855 | – | – |
|
23
CG Oncology
CGON
$2.04B
| $24.3M | 1.14% | 770,000 | – | – |
|
24
PepGen
PEPG
$38M
| $24M | 1.12% | 1,502,788 | – | – |
|
25
Merus
MRUS
$4.98B
| $22.1M | 1.03% | 373,100 -373,379 | -50% | -$22.1M |
|